US Biotechnology and Pharmaceuticals: Notable quotes from 2Q: Week1

First-page research excerpt

Vi ewp oint |

31 Jul 2026 14:19:45 ET │ 16 pages

US Biotechnology and

Pharmaceuticals

Notable quotes from 2Q: Week 1

n

CITI'S TAKE

With 2Q earnings season underway, we highlight key quotes from the largecap biotech and pharma companies including our coverage and beyond. We

highlight commentary from leadership teams in Biopharma on the following

topics: 1) AI initiatives, 2) capital allocation/ BD and 3) the GLP-1 landscape.

We included quotes from each of these themes for the companies below.

Please click through to see quotes across Biopharma.

Commentary on AI

GSK: “I'll tell you more about it, Steve, when we talk about early R&D and how we're

applying AI, not just to the idea of matching targets and patients and opportunity,

but designing molecules and ultimately making clinical trial execution more

effective. We've got 150 people in our AI group. These folks have PhDs in maths. We

don't unwrap other people's shrink-wrapped AI products.”

Geoff Meacham, Ph.D. AC

Nishant Gandhi, Ph.D.

Mary Kate Davis

Jarwei Fang

Bristol: “Over the past several years, BMS has embedded AI across its research and

enterprise operations, and demand for compute has grown alongside the scale and

maturity of our AI capabilities. In support of this expansion, we've recently

announced partnership agreements with both Anthropic and NVIDIA. Concretely,

this will help our scientists do three things, understand disease biology more

deeply, design and test candidate molecules faster, and make earlier, better

informed decisions about which programs to move forward.”

Commentary on BD/Capital allocation

Regeneron: “I don't think I expressed an aversion to M&A. I think I expressed an

aversion to overpaying in M&A settings, and we have been involved in many of

these interested transactions, and we have seen people pay far more than we think

the value would justify.”

Commentary on GLP-1 landscape

Regeneron: “Everybody is trying to compete by getting a few more percentage

points of weight loss and so forth. Whereas what we're trying to do is provide a

fundamentally substantially different profile. So imagine if somebody had invented

…